{
    "clinical_study": {
        "@rank": "50256", 
        "acronym": "CTCHNSCC01", 
        "biospec_descr": {
            "textblock": "Blood samples were drawn by standard procedure, stored in EDTA-coating tubes in 4 degree\n      temperature, then sent for CTCs counting and analysis."
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on\n      CTCs could be a prognostic factor or predictive factor to patients with head neck cancer."
        }, 
        "brief_title": "Prognostic Value of CTC in HNSCC Patients", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Recurrence", 
            "Metastasis", 
            "Death"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Neoplastic Cells, Circulating", 
                "Neoplasm Metastasis", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Histologically or cytopathologically proven head and neck squamous cell carcinoma\n           (HNSCC)\n\n        2. Disease status: locally advanced or recurrent/metastasized at initial presentation\n\n        3. Age >=20 years old\n\n        4. Could understand and signed the informed consents of this study\n\n        5. Enrolled patients were classified into three distinct subgroups:\n\n             1. Patients underwent curative surgery followed by adjuvant chemoradiotherapy (CRT)\n                because of some pathologic features such as positive margin, pathologic N2, and\n                extracapsular spread (ECS) of involved lymph nodes indicating early relapse\n                according to recommendation from National Comprehensive Cancer Network(NCCN)\n                guidelines;\n\n             2. Patients with advanced disease directly underwent definitive concurrent\n                chemoradiotherapy(CCRT);\n\n             3. Patients were to have palliative chemotherapy for existence of distant metastasis\n                or poor general condition for definitive CCRT.\n\n        6. Blood samples were collected within 7 days before the first dose of chemotherapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically or cytopathologically proven head and neck squamous cell carcinoma Age\n             \u2265 20 years. Measurable or evaluable disease according to Response Evaluation Criteria\n             In Solid Tumors(RECIST) criteria.\n\n        Ability to sign informed consent.\n\n        Exclusion Criteria:\n\n          -  Prior cancers within 5 years, except for non-melanoma skin cancers, and in situ\n             cervical cancers.\n\n        Inability to comply with study and/or follow-up procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Locally advanced or recurrent/metastatic head and neck cancer"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884129", 
            "org_study_id": "CTCHNSCC01", 
            "secondary_id": "CMRPG3B0971~3"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Circulating tumor cells", 
            "Head and neck cancer", 
            "Squamous cell carcinoma", 
            "Survival", 
            "Prognosis"
        ], 
        "lastchanged_date": "June 19, 2013", 
        "location": {
            "contact": {
                "email": "sally6869@cgmh.org.tw", 
                "last_name": "Tsang-Tang Hsieh, M.D", 
                "phone": "+886-33281200", 
                "phone_ext": "8825"
            }, 
            "contact_backup": {
                "email": "wisdom5000@gmail.com", 
                "last_name": "Chia-Hsun Hsieh, M.D,M.S.", 
                "phone": "+886-33281200", 
                "phone_ext": "8825"
            }, 
            "facility": {
                "address": {
                    "city": "Taoyuan", 
                    "country": "Taiwan", 
                    "zip": "333"
                }, 
                "name": "Chang Gung Memorial Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Chia-Hsun Hsieh, M.D, M.S", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ching-Ping Tseng, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Hung-Ming Wang, M.D", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prognostic Value of Circulating Tumor Cells in Patients With Locally Advanced and Metastatic/Recurrent Head and Neck Cancer", 
        "other_outcome": {
            "description": "All causes of death would be documented and the relationship between CTCs number and time from CTCs checkpoint to death will be analyzed.", 
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "overall_official": {
            "affiliation": "Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou", 
            "last_name": "Chia-Hsun C Hsieh, M.D, M.S.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measure response or progression events via all available imaging studies, including Chest-Xray, CT scans, or MRI, PET study. The relationship between CTCs number and time from CTCs checkpoint to disease progression will be analyzed.", 
            "measure": "Progression-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884129"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Chang Gung Memorial Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chang Gung Memorial Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "12 Months", 
        "verification_date": "February 2013"
    }
}